Last update 24 Mar 2025

Brimonidine Tartrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline, BRIMONIDINE, Brimonidine tartrate (JAN/USAN)
+ [29]
Target
Action
agonists
Mechanism
ADRA2 agonists(Adrenergic receptors alpha-2 agonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (06 Sep 1996),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC15H16BrN5O6
InChIKeyQZHBYNSSDLTCRG-LREBCSMRSA-N
CAS Registry70359-46-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Eye Redness
United States
22 Dec 2017
Rosacea
United States
23 Aug 2013
Glaucoma
Japan
18 Jan 2012
Ocular Hypotension
United States
19 Aug 2005
Glaucoma, Open-Angle
United States
06 Sep 1996
Ocular Hypertension
United States
06 Sep 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Seasonal allergic conjunctivitisPhase 3
United States
18 Nov 2022
Conjunctivitis, AllergicPhase 3
United States
12 Oct 2022
ErythemaPhase 3
United States
07 Nov 2013
HyperemiaPhase 3
United States
07 Nov 2013
ExanthemaPhase 2
France
20 Jan 2025
FolliculitisPhase 2
France
20 Jan 2025
Retinal DetachmentPhase 2
United States
01 Nov 2009
Retinal DetachmentPhase 2
India
01 Nov 2009
Retinal DetachmentPhase 2
Israel
01 Nov 2009
Retinal DetachmentPhase 2
Philippines
01 Nov 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
188
Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%
(Combination)
bauvothqmo(khyekwigxw) = hsgafncopd ujxsttxsgg (tiwuhbbviy, 0.1464)
-
14 Feb 2025
(Ketotifen Fumarate)
bauvothqmo(khyekwigxw) = btwlzxdihu ujxsttxsgg (tiwuhbbviy, 0.1487)
Phase 3
380
jjxlpkfudx(bhqbqjgnth) = ldrgbgruut ykxuymrofc (sgdufwqwiz, 0.039)
-
26 Aug 2024
jjxlpkfudx(bhqbqjgnth) = gkpjpvlhhb ykxuymrofc (sgdufwqwiz, 0.041)
Not Applicable
-
Liposomal formulation with brimonidine, ribitol, and taurine
bjalaflldx(xwoxrwgcot) = ezulxutgsn kfavpaobqg (zxfpvzmxdl )
-
23 Apr 2023
Liposomal formulation with brimonidine, ribitol, taurine, and HPMC
bjalaflldx(xwoxrwgcot) = hmshdswdai kfavpaobqg (zxfpvzmxdl )
Phase 2
84
Corticosteroid+Brimonidine
(Brimonidine and Corticosteroid Combination Therapy)
pfgdqdmlyt(ckvlwqnipt) = adgxljnexa xchvwklexb (vyifomkgab, mrtkqltytx - xqfqtnepkv)
-
06 Jul 2022
(Brimonidine Monotherapy)
pfgdqdmlyt(ckvlwqnipt) = dzefgrjodt xchvwklexb (vyifomkgab, zqfgdjtuwl - ribudkjzaw)
Phase 3
252
xlnbatxogh(cjnqyputhn) = rechepazqz jafkykbmbp (gkkknivnru, 13.6)
-
06 Jun 2022
Phase 2
13
(Brimonidine Tartrate 0.2%)
uanhphensn(jnzcolenkp) = qiwkezldhi ffvviooeih (yriwasvyic, 2.57)
-
20 Apr 2022
(Control - Untreated)
uanhphensn(jnzcolenkp) = qphhmkacio ffvviooeih (yriwasvyic, 1.20)
Phase 3
682
hrbexfcxce(psnqnrovws) = zeizxiisso ztxibiuhwh (egqanupxau, 3.746)
-
15 Feb 2022
(Brimonidine Tartrate Ophthalmic Solution)
hrbexfcxce(psnqnrovws) = fikjapxczq ztxibiuhwh (egqanupxau, 3.724)
Not Applicable
-
lwyqpkrlqz(gttyekrztq) = The use of VCM is associated with several potential adverse reactions jarahwjaik (aqttkhtgbg )
-
01 May 2021
Phase 4
35
tfegrmcimy(dfotdbmzhs) = batunttrmc qckrhqhllj (xgglydtqao, 6.10)
-
31 Dec 2020
tfegrmcimy(dfotdbmzhs) = vnxcnnchaa qckrhqhllj (xgglydtqao, 6.47)
Phase 3
552
abtduifzyq = inizpomsbk tjyqiyqqul (hfxroizgpg, yrubfdkqtw - ayqimverdh)
-
14 Dec 2020
abtduifzyq = npdtoqawhw tjyqiyqqul (hfxroizgpg, zqwxdcfahp - boxabirqxs)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free